About Crossject
Crossject is a company based in Dijon (France) founded in 2001. Crossject has raised $40.33 million across 6 funding rounds from investors including Rothschild & Co, GSK and European Union. The company has 108 employees as of December 31, 2024. Crossject offers products and services including ZENEO®. Crossject operates in a competitive market with competitors including scPharmaceuticals, Valeritas, CeQur, Vaxxas and Incline Therapeutics, among others.
- Headquarter Dijon, France
- Employees 108 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Crossject Sa
-
Annual Revenue
Not available
-
Net Profit
-$13.29 M (USD)-48.12as on Dec 31, 2024
-
EBITDA
-$10.75 M (USD)-4.47as on Dec 31, 2024
-
Total Equity Funding
$40.33 M (USD)
in 6 rounds
-
Latest Funding Round
$55.39 K (USD), Grant
Aug 01, 2019
-
Investors
Rothschild & Co
& 6 more
-
Employee Count
108
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Crossject
Crossject is a publicly listed company on the EURONEXT with ticker symbol ALCJ in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of Crossject
Crossject offers a comprehensive portfolio of products and services, including ZENEO®.
Needle-free device for delivering emergency medications quickly.
Funding Insights of Crossject
Crossject has successfully raised a total of $40.33M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $55.39 thousand completed in August 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Crossject
Crossject has secured backing from 7 investors, including institutional and venture fund investors. Prominent investors backing the company include Rothschild & Co, GSK and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
A Plus Finance is engaged in investment management and financing services.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
PE investment firm investing primarily in France
|
Locked | Locked | Locked |
Investor details for Crossject
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Crossject
Investment portfolio details for Crossject
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Crossject
Detailed financials for Crossject
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Crossject Comparisons
Peer comparison for Crossject
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Crossject
Crossject operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as scPharmaceuticals, Valeritas, CeQur, Vaxxas and Incline Therapeutics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of a device for subcutaneous drug delivery for the treatment of bacterial infections and heart failure
|
|
| Locked | Locked | Locked |
Wearable insulin patch pumps are developed for transdermal delivery.
|
|
| Locked | Locked | Locked |
Wearable insulin delivery patches are developed for mealtime dosing.
|
|
| Locked | Locked | Locked |
Developer of vaccines to treat cancer and infectious diseases
|
|
| Locked | Locked | Locked |
Hospital-focused specialty pharmaceuticals are developed for acute pain management.
|
Detailed competitors of Crossject
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Crossject
Complete news archive for Crossject
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Crossject
Crossject was founded in 2001.
Crossject is headquartered in Dijon, France. It is registered at Dijon, Bourgogne-franche-comte, France.
Crossject is a funded company, having raised a total of $40.33M across 6 funding rounds to date.
As of Dec 31, 2024, the latest employee count at Crossject is 108.
CROSSJECT developed a needle-free injection platform called Zeneo, which is designed to improve patients safety, claimed to provide comfort and to enable a better observance of treatments. The product is a pre-fillable, needle-free injection system that is claimed to deliver drugs intradermally, subcutaneously, and intramuscularly, the company is developing a portfolio of products combining well-known drugs with an innovative injection mode, particularly adapted to emergency situations and most chronic treatments, with a device adaptable to many specific situations.
Crossject's top competitors include scPharmaceuticals, Vaxxas and CeQur.
Crossject offers ZENEO®.
Yes, Crossject is publicly traded on EURONEXT under the ticker symbol ALCJ.
Crossject has 7 investors. Key investors include Rothschild & Co, GSK, European Union, A Plus Finance, and Sofimac Investment Managers.
The ticker symbol of Crossject is ALCJ on EURONEXT.